Cantor Fitzgerald Reiterates Overweight on Pacific Biosciences, Maintains $3.5 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Ross Osborn has reiterated an Overweight rating on Pacific Biosciences (NASDAQ:PACB) and maintained a price target of $3.5.
August 08, 2024 | 2:42 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Ross Osborn has reiterated an Overweight rating on Pacific Biosciences (NASDAQ:PACB) and maintained a price target of $3.5.
The reiteration of an Overweight rating and the maintenance of a $3.5 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100